Core Concept: Monthly Supervised Dose in WHO Multibacillary MDT
The three-drug regimen for multibacillary leprosy combines
rifampicin,
dapsone, and
clofazimine. The distinctive feature tested here is the
split between the once-monthly supervised dose and the daily self-administered dose. Understanding this split matters because the nurse at the RHU must know exactly which drugs to give during the supervised visit and which drugs the client takes at home.
Key point! Rifampicin is given only once a month because it is the most potent bactericidal drug in the regimen and a single monthly dose is sufficient to kill rapidly multiplying
Mycobacterium leprae. Clofazimine is given at two different doses: a higher monthly dose and a lower daily dose. Dapsone is the only drug given at the same dose every day.
| Drug | Supervised monthly visit | Daily self-administered | Pattern |
|---|
| Rifampicin | 600 mg once | None | Monthly only |
| Clofazimine | 300 mg once | 50 mg daily | Higher monthly + lower daily |
| Dapsone | 100 mg | 100 mg daily | Same dose every day |
The correct answer is therefore
rifampicin and a higher dose of clofazimine. Rifampicin appears only at the monthly visit, and clofazimine is given at a higher dose on that day than on the other days. Dapsone keeps the same dose throughout.
Watch out! Do not confuse the monthly clofazimine dose with the daily clofazimine dose. The monthly dose is
300 mg, while the daily dose is only
50 mg. This difference is the reason option 2 is correct and option 4 is wrong.
The rationale for this design is both pharmacological and practical. Rifampicin has a long post-antibiotic effect against
M. leprae, so intermittent monthly administration remains effective while reducing the risk of hepatotoxicity that would accompany daily use. Clofazimine has a very long half-life and accumulates in tissues, so a higher monthly dose helps maintain therapeutic tissue levels while the lower daily dose reduces gastrointestinal intolerance and skin discoloration. Dapsone, in contrast, requires consistent daily dosing because its bacteriostatic action depends on maintaining steady plasma concentrations.
From the nursing process perspective, the supervised monthly visit is the moment when the nurse directly observes rifampicin and the higher clofazimine dose being taken. This ensures adherence to the most critical bactericidal component of the regimen and provides an opportunity to monitor for adverse effects such as rifampicin-related hepatotoxicity, reddish discoloration of urine and body fluids, and clofazimine-related skin pigmentation. The daily dapsone and low-dose clofazimine are dispensed in blister packs for home use, and the nurse must teach the client to take them consistently even on days when no supervised visit occurs.
The monthly supervised component is the backbone of leprosy control because it guarantees delivery of the most powerful bactericidal drug under direct observation, while the daily component maintains suppression of bacterial growth between visits. This structure also supports the public health goal of reducing transmission, since a client who receives rifampicin under supervision is confirmed to have taken the drug that most rapidly renders them non-infectious.
The newer regimens mentioned in the evidence, such as those combining rifampicin with moxifloxacin and clarithromycin, are investigational alternatives aimed at shortening treatment duration and improving bacterial clearance. However, the standard WHO-MDT described in the basic explanation remains the reference regimen for the DOH Leprosy Control Program, and the monthly supervised rifampicin plus higher-dose clofazimine pattern is the key point for licensure examination purposes.